Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease
详细信息 查看全文
- 作者：Miles C. Miller ; Rosemarie Tavares ; Conrad E. Johanson ; Virginia Hovanesian ; John E. Donahue ; Liliana Gonzalez ; Gerald D. Silverberg ; Edward G. Stopa
- 关键词：Alzheimer's disease ; RAGE ; Blood– ; brain barrier ; Hippocampus ; β ; -amyloid peptide ; Microvessels
- 刊名：Brain Research
- 出版年：2008
- 出版时间：16 September 2008
- 年：2008
- 卷：1230
- 期：Complete
- 页码：273-280
- 全文大小：1682 K
文摘
Microvascular accumulation and neuronal overproduction of amyloid-β peptide (Aβ) are pathologic features of Alzheimer's disease (AD). In this study, we examined the receptor for advanced glycation endproducts (RAGE), a multi-ligand receptor found in both neurons and cerebral microvascular endothelia that binds Aβ. RAGE expression was assessed in aged controls (n = 6), patients with early AD-like pathology (n = 6), and severe, Braak V–VI AD (n = 6). Human hippocampi were stained with a specific polyclonal antibody directed against RAGE (Research Diagnostics, Flanders, NJ). Immunoreactivity was localized in both neurons and cerebral endothelial cells. Quantitative image-analyses were performed on grayscale images to assess the total surface area of endothelial RAGE immunoreaction product in cross sections of cerebral microvessels (5–20 µm). Confocal images were acquired for confirmation of RAGE immunoreactivity in both microvessels and neurons by coupling RAGE with CD-31 and neurofilament, respectively. A significant increase in endothelial RAGE immunoreactivity was found in severe Braak V–VI AD patients when compared to aged controls (p < 0.001), and when compared to patients with early AD pathology (p = 0.0125). In addition, a significant increase in endothelial RAGE immunoreactivity was witnessed when comparing aged controls having no reported AD pathology with patients having early AD-like pathology (p = 0.038). Our data suggest that microvascular RAGE levels increase in conjunction with the onset of AD, and continue to increase linearly as a function of AD pathologic severity (p < 0.0001).